CLINICAL TRIALS PROFILE FOR MENOPUR
✉ Email this page to a colleague
All Clinical Trials for MENOPUR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00257556 ↗ | A Study of the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant Follitropin Alfa | Completed | Ferring Pharmaceuticals | Phase 4 | 2005-10-01 | Prospective open label, randomised, parallel group, comparative pilot. |
| NCT00335894 ↗ | Clinical Study of Clinical Efficacy and Tolerability of hMG-IBSA s.c.in Women Undergoing COH in an ART Programme (IVF). | Completed | IBSA Institut Biochimique SA | Phase 3 | 2005-05-01 | Multicenter, prospective, randomized, investigator blind, controlled clinical trial. Two parallel groups, one receiving the test drug hMG (hMG-IBSA, IBSA Institut Biochimique sa) and the other the reference drug hMG (Menopur, Ferring Pharmaceuticals, Inc.). |
| NCT00492934 ↗ | What is the Best Preparation for Embryo Transfer in Cryo Cycles: a Natural Cycle or Light Hormonal Stimulation? | Unknown status | University Hospital, Gasthuisberg | N/A | 2004-01-01 | The study investigates if, among women with a regular cycle (between 25 and 45 days), the endometrium is better prepared for the transfer of an embryo that was cryopreserved and if the subsequent embryo implantation rate is higher when the cycle is started with daily, small-dose hormonal injections than in cycles without these daily injections. |
| NCT00802360 ↗ | MENOPUR® Versus FOLLISTIM® | Completed | Ferring Pharmaceuticals | Phase 4 | 2008-12-01 | To compare the efficacy and safety of highly purified menotropin (Menopur®) with that of follitropin beta (FOLLISTIM®) in patients who are undergoing gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles |
| NCT00805935 ↗ | Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS) | Completed | Ferring Pharmaceuticals | Phase 4 | 2009-01-01 | This multicenter, randomized, open-label exploratory study will be performed in approximately 200 polycystic ovary syndrome (PCOS) but otherwise healthy females undergoing in vitro fertilization (IVF). Each study center will follow its standard practice for in vitro fertilization (IVF) within the study parameters as noted in this protocol. The study centers will use marketed products purchased from Schraft's Pharmacy for all phases of the study (down-regulation, stimulation, ovulation induction, and luteal support). Subjects will be randomly assigned to highly purified menotropin (Menopur®) or follitropin beta (Follistim Pen®) for stimulation and progesterone vaginal insert (Endometrin®) or progesterone in oil for luteal support. Subjects will return to the study center for regular scheduled clinic visits as required per in vitro fertilization (IVF) protocol at the site and at specified times during the cycle (Stimulation Day 6, Day of human chorionic gonadotropin (hCG), and first serum pregnancy test) for estradiol (E2), progesterone (P4) and human chorionic gonadotropin (hCG) labs. All subjects will be required to complete a final study visit at completion of luteal support or negative serum pregnancy test following embryo transfer. |
| NCT00884221 ↗ | MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer | Completed | Ferring Pharmaceuticals | Phase 3 | 2009-07-01 | The main purpose of this clinical research trial was to compare the ongoing pregnancy rate between two gonadotrophins for controlled ovarian stimulation (MENOPUR and recombinant follicle-stimulating hormone (FSH)), in cycles where a gonadotrophin-releasing hormone (GnRH) antagonist was used for prevention of premature luteinizing hormone (LH) surge and where a single embryo was transferred at the blastocyst stage. |
| NCT00971152 ↗ | Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle | Completed | Ferring Pharmaceuticals | Phase 3 | 2009-09-01 | This goal of this study is to evaluate the outcomes from in vitro fertilization cycles where a 450 IU daily dose of gonadotropins is administered compared to those where a 600 IU daily dose is administered for women who are at risk of a poor ovarian response in order to determine if one dose or the other results in improved cycle outcomes. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MENOPUR
Condition Name
Clinical Trial Locations for MENOPUR
Trials by Country
Clinical Trial Progress for MENOPUR
Clinical Trial Phase
Clinical Trial Sponsors for MENOPUR
Sponsor Name
